Beneath the Surface: Psoriatic Arthritis in Your Patients With Psoriasis

This interactive session included three practice-oriented and succinctly delivered presentations in addition to a case simulation. The first presentation reviewed the role of dermatology providers in psoriatic arthritis (PsA) care, highlighting the importance of screening patients with psoriasis for PsA in order to timely diagnose PsA and start treatment that can prevent or reduce joint damage. The second presentation addressed the wide range of PsA therapies and the latest evidence-based recommendations for treatment of PsA. The third presentation focused on appropriate monitoring of patients with PsA. In the simulation exercise, participants explored a clinical vignette of a patient with psoriasis and PsA and make a treatment decision choosing from the available options. At the end of the session, the faculty discussed patient-centered care for patients with psoriasis and PsA and invited questions from the audience.

Date: June 23, 2018

Venue: International Center North, The Broadmoor, Colorado Springs, Colorado

Review activity content under the Materials button (below).



Neil J. Korman, MD, PhD

Director, Clinical Trials Unit
Clinical Director, Murdough Family Center for Psoriasis
Professor, Dermatology
University Hospitals Cleveland Medical Center
Case Western Reserve University School of Medicine
Cleveland, Ohio

Rebecca R. Muntean, MD, ND, FACR

Clinical Rheumatologist,
Providence Health & Services
Faculty, University of Washington WWAMI Regional Medical Education
Faculty, Providence Spokane Internal Medicine
Investigator, Premier Clinical Research
Providence Health & Services
Spokane, Washington

Learning Objectives

As a result of participation in this educational activity, participants should increase their ability to:

Screen patients with psoriasis for psoriatic arthritis (PsA) at every visit

Discuss best evidence for choosing optimal therapy for patients with PsA

Optimize monitoring for adherence to treatment, achievement of treatment targets, adverse events, and comorbidities in patients with psoriasis and PsA

Explore best practices for dermatology and rheumatology providers in working together to improve timely diagnosis and treatment of PsA

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of this activity.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative): Marianna Shershneva, MD, PhD and Jessica Porucznik

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Presenter: Neil J. Korman, MD, PhD: advisor for AbbVie Inc., Celgene Corporation, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., and Regeneron Pharmaceuticals, Inc.; investigator for AbbVie Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Pfizer Inc., and Regeneron Pharmaceuticals, Inc.; speaker for AbbVie Inc., Celgene Corporation, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., and Novartis; and consultant for Novartis and Pfizer Inc.
  • Presenter: Rebecca R. Muntean, MD, ND, FACR: speaker for Janssen Pharmaceuticals Inc.
  • Planner: Lakshi Aldredge, MSN, ANP-BC: consultant and speaker for AbbVie Inc., Celgene Corporation, Eli Lilly and Company, Novartis, Sanofi, and Regeneron Pharmaceuticals, Inc.
  • Planner (Forefront Collaborative): Lily Zurkovsky, PhD: has personal stock in Teva Pharmaceutical Industries Ltd.

Activity Information

Target Audience
The target audience for this educational activity was nurse practitioners and physician assistants who specialize in dermatology. Dermatologists and other clinicians who are members of the healthcare team providing care for patients with psoriasis may have benefited from participation in the activity. 

Accreditation Statement
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Forefront Collaborative designated this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Interstate Postgraduate Medical Association is approved by the California Board of Registered Nursing, Provider Number 6971, for 1.5 contact hours. Each person should retain this certificate for 4 years after the course has been completed. RNs outside of California must verify with their licensing agency for approval of this course.

This activity was approved for 1.25 contact hour(s) of continuing education (which includes 0.92 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 18053214. This activity was planned in accordance with AANP CE Standards and Policies.

CME Content Review
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, Interstate Postgraduate Medical Association, or Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity included reference(s) to unlabeled or unapproved uses of drugs.

This activity is provided by Forefront Collaborative in collaboration with Interstate Postgraduate Medical Association.

Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit

Not Enrolled
This course is currently closed